TARA
Protara Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
3.98
▲ 0.08 (2.05%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.83
Prev close
3.90
Day high
3.95
Day low
3.81
Volume
238.44K
Market cap
$227.52M
P/E (TTM)
—
52W range
3.02 – 7.82
Day trading desk
Gap from prior close
-1.79%
Prior close 3.90
VWAP
3.86
+2.98% from price
Relative volume
0.41×
Quiet session
Session range
13.71%
3.50 – 3.98
Position in range
100%
Near session high
ATR (14D)
0.15
3.87% of price
Prior day high
3.93
PDH
Prior day low
3.83
PDL
Bid / ask spread
—
Quote not published
Session volume
240.22K
Avg 581.40K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.02%
-1.7%
1M
-4.70%
-8.4%
3M
-22.54%
-25.6%
6M
-43.71%
-54.8%
YTD
-27.77%
-40.1%
1Y
+27.06%
+7.1%
3Y
+65.24%
-8.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TARA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+6.27K
Net buying
Buy transactions
2
245.69K shares
Sell transactions
3
239.42K shares
Net transactions
+5
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
1.36M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | SHEFFERMAN JESSE Chief Executive Officer |
STOCK | 30.00K | $0 | Direct |
| Jun 29, 26 | SHEFFERMAN JESSE Chief Executive Officer |
SELL | 215.69K | $882.16K | Direct |
| Jun 29, 26 | SHEFFERMAN JESSE Chief Executive Officer |
CONVERSION | 215.69K | $411.96K | Direct |
| Apr 8, 26 | ZUMMO JACQUELINE Officer |
SELL | 1.13K | $6.12K | Direct |
| Apr 1, 26 | ZUMMO JACQUELINE Officer |
SELL | 22.60K | $118.86K | Direct |
| Jan 16, 26 | FABBIO PATRICK Chief Financial Officer |
STOCK | 28.00K | $0 | Direct |
| Jan 16, 26 | SHEFFERMAN JESSE Chief Executive Officer |
STOCK | 87.00K | $0 | Direct |
| Jan 16, 26 | ZUMMO JACQUELINE Chief Operating Officer |
STOCK | 30.00K | $0 | Direct |
| Jan 16, 26 | CONKLING WILLIAM Officer |
STOCK | 26.00K | $0 | Direct |
| Jan 16, 26 | FRY HANNAH Officer |
STOCK | 9.50K | $0 | Direct |
| Jan 16, 26 | NICACIO LEONARDO VIANA M.D. Officer |
STOCK | 26.00K | $0 | Direct |
| Jun 27, 25 | SHEFFERMAN JESSE Chief Executive Officer |
STOCK | 18.67K | $0 | Direct |
| Jun 24, 25 | SHEFFERMAN JESSE Chief Executive Officer |
STOCK | 300.00K | $0 | Direct |
| Jun 2, 25 | CONKLING WILLIAM Officer |
STOCK | 50.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CONKLING WILLIAM |
Officer | 76.00K | Stock Award(Grant) |
FABBIO PATRICK |
Chief Financial Officer | 70.44K | Stock Award(Grant) |
FRY HANNAH |
Officer | 46.31K | Stock Award(Grant) |
LEVY RICHARD S |
Director | 51.00K | Purchase |
NICACIO LEONARDO VIANA M.D. |
Officer | 78.18K | Stock Award(Grant) |
OPALEYE MANAGEMENT, INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SHEFFERMAN JESSE |
Chief Executive Officer | 991.83K | Stock Gift |
ZUMMO JACQUELINE |
Officer | 94.83K | Sale |
Fundamentals
Market cap$227.52M
Enterprise value$87.77M
Revenue (TTM)—
Gross profit—
EBITDA$-76.45M
Net income$-70.02M
EPS (TTM)$-1.36
Free cash flow$-40.49M
Total cash$142.49M
Total debt$2.75M
Book value / share$3.29
Shares outstanding59.10M
Float54.88M
Short % of float8.14%
Dividend yield—
Beta (5Y)1.49
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.28
PEG ratio—
Price / sales—
Price / book1.17
EV / revenue—
EV / EBITDA-1.15
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-45.80%
Return on assets-28.82%
Debt / equity1.70
Current ratio10.97
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $42.63M | $31.70M | $24.99M | $16.81M | +34.5% |
| Selling, general & admin | $21.92M | $17.45M | $18.62M | $20.74M | +25.6% |
| Total operating expense | $64.55M | $49.15M | $43.61M | $37.55M | +31.3% |
| Operating income | -$64.55M | -$49.15M | -$43.61M | -$37.55M | -31.3% |
| Net interest income | $6.33M | $4.13M | $3.18M | $1.09M | +53.1% |
| Pre-tax income | -$57.44M | -$44.60M | -$40.42M | -$65.95M | -28.8% |
| Net income | -$57.44M | -$44.60M | -$40.42M | -$65.95M | -28.8% |
| Net income to common | -$57.44M | -$44.60M | -$40.42M | -$65.95M | -28.8% |
| Basic EPS | -1.34 | -2.17 | -3.57 | -5.86 | +38.2% |
| Diluted EPS | -1.34 | -2.17 | -3.57 | -5.86 | +38.2% |
| EBIT | -$64.55M | -$49.15M | -$43.61M | -$64.81M | -31.3% |
| EBITDA | -$64.19M | -$48.82M | -$43.27M | -$64.57M | -31.5% |
| Basic shares | 42.84M | 20.59M | 11.33M | 11.26M | +108.0% |
| Diluted shares | 42.84M | 20.59M | 11.33M | 11.26M | +108.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $49.66M | $162.80M | $39.59M | $24.13M | -69.5% |
| Cash & short-term investments | $155.55M | $170.29M | $65.58M | $84.37M | -8.7% |
| Total current assets | $159.50M | $172.16M | $68.70M | $86.15M | -7.3% |
| Property, plant & equipment | $3.93M | $5.28M | $6.56M | $7.87M | -25.5% |
| Goodwill & intangibles | $2.93M | $3.25M | $2.66M | $84.00K | -9.7% |
| Total assets | $209.47M | $181.45M | $78.95M | $113.29M | +15.4% |
| Total current liabilities | $10.94M | $10.96M | $6.15M | $5.74M | -0.2% |
| Total debt | $3.36M | $4.48M | $5.47M | $6.38M | -25.1% |
| Total liabilities | $13.06M | $14.32M | $10.63M | $11.21M | -8.8% |
| Retained earnings | -$302.42M | -$244.98M | -$200.38M | -$159.96M | -23.4% |
| Shareholder equity | $196.41M | $167.13M | $68.32M | $102.08M | +17.5% |
| Working capital | $148.56M | $161.19M | $62.56M | $80.41M | -7.8% |
| Net tangible assets | $193.48M | $163.89M | $65.66M | $102.00M | +18.1% |
| Shares issued | 53.59M | 35.04M | 11.36M | 11.27M | +52.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$57.44M | -$44.60M | -$40.42M | -$65.95M | — | -28.8% |
| Depreciation & amortisation | $362.00K | $332.00K | $341.00K | $248.00K | — | +9.0% |
| Stock-based compensation | $3.83M | $4.13M | $6.09M | $6.69M | — | -7.2% |
| Change in working capital | -$2.94M | $4.01M | -$4.14M | $539.00K | — | -173.4% |
| Operating cash flow | -$56.37M | -$35.81M | -$37.56M | -$26.46M | — | -57.4% |
| Capital expenditure | -$94.00K | -$63.00K | -$45.00K | -$120.00K | — | -49.2% |
| Investing cash flow | -$139.49M | $19.16M | $53.11M | $14.95M | — | -828.2% |
| Share buybacks | — | — | -$91.00K | -$90.00K | -$228.00K | — |
| Financing cash flow | $82.72M | $139.87M | -$91.00K | -$90.00K | — | -40.9% |
| Free cash flow | -$56.46M | -$35.87M | -$37.60M | -$26.58M | — | -57.4% |
| End cash position | $50.40M | $163.54M | $40.33M | $24.87M | — | -69.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $13.56M | $13.12M | $9.59M | $10.77M | $9.15M | +3.3% |
| Selling, general & admin | $6.07M | $5.96M | $5.17M | $5.82M | $4.98M | +1.9% |
| Total operating expense | $19.63M | $19.08M | $14.76M | $16.59M | $14.12M | +2.9% |
| Operating income | -$19.63M | -$19.08M | -$14.76M | -$16.59M | -$14.12M | -2.9% |
| Net interest income | $1.84M | $1.50M | $1.50M | $1.61M | $1.72M | +22.4% |
| Pre-tax income | -$17.78M | -$17.31M | -$13.26M | -$14.96M | -$11.91M | -2.7% |
| Net income | -$17.78M | -$17.31M | -$13.26M | -$14.96M | -$11.91M | -2.7% |
| Net income to common | -$17.78M | -$17.31M | -$13.26M | -$14.96M | -$11.91M | -2.7% |
| Basic EPS | -0.31 | -0.37 | -0.31 | -0.35 | -0.29 | +16.2% |
| Diluted EPS | -0.31 | -0.37 | -0.31 | -0.35 | -0.29 | +16.2% |
| EBIT | -$19.63M | -$19.08M | -$14.76M | -$16.59M | -$14.12M | -2.9% |
| EBITDA | -$19.54M | -$18.99M | -$14.67M | -$16.49M | -$14.04M | -2.9% |
| Basic shares | 57.54M | 46.04M | 42.27M | 42.27M | 40.71M | +25.0% |
| Diluted shares | 57.54M | 46.04M | 42.27M | 42.27M | 40.71M | +25.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.74M | $49.66M | $12.55M | $31.50M | $91.46M | -70.3% |
| Cash & short-term investments | $135.79M | $155.55M | $132.67M | $122.22M | $124.36M | -12.7% |
| Total current assets | $140.00M | $159.50M | $135.64M | $125.09M | $126.53M | -12.2% |
| Property, plant & equipment | $3.56M | $3.93M | $4.28M | $4.64M | $4.98M | -9.5% |
| Goodwill & intangibles | $5.90M | $2.93M | $2.99M | $3.04M | $3.11M | +101.5% |
| Total assets | $191.92M | $209.47M | $144.64M | $156.93M | $168.56M | -8.4% |
| Total current liabilities | $8.92M | $10.94M | $9.91M | $9.76M | $7.02M | -18.4% |
| Total debt | $3.06M | $3.36M | $3.66M | $3.95M | $4.23M | -9.0% |
| Total liabilities | $10.71M | $13.06M | $12.35M | $12.51M | $10.07M | -17.9% |
| Retained earnings | -$320.20M | -$302.42M | -$285.11M | -$271.85M | -$256.89M | -5.9% |
| Shareholder equity | $181.21M | $196.41M | $132.29M | $144.42M | $158.48M | -7.7% |
| Working capital | $131.07M | $148.56M | $125.73M | $115.33M | $119.51M | -11.8% |
| Net tangible assets | $175.30M | $193.48M | $129.30M | $141.38M | $155.37M | -9.4% |
| Shares issued | 55.06M | 53.59M | 38.59M | 38.58M | 38.58M | +2.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.78M | -$17.31M | -$13.26M | -$14.96M | -$11.91M | -2.7% |
| Depreciation & amortisation | $90.00K | $93.00K | $88.00K | $98.00K | $83.00K | -3.2% |
| Stock-based compensation | $1.36M | $1.04M | $1.05M | $903.00K | $833.00K | +30.6% |
| Change in working capital | -$5.11M | -$731.00K | -$206.00K | $1.81M | -$3.81M | -598.5% |
| Operating cash flow | -$21.34M | -$16.95M | -$12.45M | -$12.25M | -$14.71M | -25.9% |
| Capital expenditure | — | -$24.00K | -$4.00K | -$22.00K | -$44.00K | — |
| Investing cash flow | -$14.72M | -$26.91M | -$6.51M | -$47.72M | -$58.35M | +45.3% |
| Financing cash flow | $1.14M | $80.96M | $13.00K | $8.00K | $1.73M | -98.6% |
| Free cash flow | -$21.34M | -$16.97M | -$12.46M | -$12.27M | -$14.76M | -25.7% |
| End cash position | $15.48M | $50.40M | $13.30M | $32.24M | $92.21M | -69.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
-35.1% from spot
ATM implied vol
166.4%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
2 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.31 | -0.36 | -14.6% |
| Mar 2026 | -0.37 | -0.31 | +15.6% |
| Dec 2025 | -0.31 | -0.38 | -21.8% |
| Sep 2025 | -0.39 | -0.31 | +19.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.31 | 7 | $0 | 0.0% |
| Next quarter | -0.36 | 6 | $0 | 0.0% |
| Current year | -1.39 | 6 | $0 | 0.0% |
| Next year | -1.69 | 7 | $1.00M | 0.0% |
Analyst targets & ownership
Mean target$25.71
High target$30.00
Low target$20.00
Implied upside546.09%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy2 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders2.30%
Held by institutions78.36%
Institutions holding155
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.95
+0.79% from price
SMA 20
3.97
-3.06% from price
SMA 50
4.02
-4.21% from price
SMA 100
4.49
-11.45% from price
SMA 200
5.18
-25.75% from price
EMA 12
3.95
+0.72% from price
EMA 26
4.00
-0.46% from price
EMA 50
4.13
-3.53% from price
RSI (14)
40.2
Neutral
MACD (12,26,9)
-0.05
Hist -0.01
ATR (14)
0.15
4.00% of price
Realised vol 30D
30.8%
Annualised
Bollinger upper
4.13
20, 2σ
Bollinger lower
3.81
20, 2σ
50 / 200 cross
Death
4.02 vs 5.18
Trend bias
Below 200
-25.75%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.02
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
30.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-51.7%
Peak to trough
Max drawdown 5Y
-86.6%
Peak to trough
ATR 14
0.15
4.00% of price
Beta (reported)
1.49
5Y monthly, from filing
Short interest
Shares short
4.50M
Prior 4.34M
Change vs prior
+3.7%
Shorts adding
% of float
8.14%
Normal
% of shares out
8.00%
Against total outstanding
Days to cover
7.5
Crowded exit
Float
54.88M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 20, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 14, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Apr 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 4, 26 | JP Morgan | INITIATED | — | Overweight |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 7, 26 | Piper Sandler | INITIATED | — | Overweight |
| Dec 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 25 | Jones Trading | INITIATED | — | Buy |
| Apr 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 16, 25 | Scotiabank | INITIATED | — | Sector Outperform |
| Mar 14, 25 | Cantor Fitzgerald | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJan 10, 2020
Last split1:40
Split dateJan 10, 2020
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-29
Corporate Changes & Voting Matters
8-K · 2026-06-15
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-20
Offering Registrations
S-3 · 2026-05-14
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-28
Proxy Statements
PRE 14A · 2026-04-17
Headlines
Protara Therapeutics: Q2 Earnings Snapshot
Associated Press · 12d ago
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
GlobeNewswire · 12d ago
What Makes Protara Therapeutics (TARA) a New Buy Stock
Zacks · 33d ago
Protara Therapeutics CMO Leonardo Viana Nicacio Resigns
MT Newswires · 54d ago
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
PR Newswire · 61d ago
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Motley Fool · 84d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.